The Verjú is the first green laser to be cleared by the FDA and the first clinically-proven, noninvasive procedure to improve the appearance of cellulite.
McKinney, TX (PRWEB) January 30, 2014
Erchonia, the global leader in low level laser healthcare applications, today unveils its newest low level laser, the Verjú. The U.S. Food and Drug Administration (FDA) has granted Erchonia 510 (k) clearance to market the Verjú for the non-invasive treatment of cellulite of the thighs, buttocks and lower abdomen as well as non-invasive body contouring of the waist, hips and thighs.
The world’s first and only green laser to receive FDA clearance, Erchonia’s Verjú laser system is made up of six green laser beams that sweep the area of concern for a treatment period of 30 minutes. Verjú’s green wavelength carries even more energy than a red wavelength so it can liberate more lipid material and contour the body while effectively stimulating the removal of cellulite.
The Verjú received FDA clearance based on a double blind, randomized, multi-site and placebo-controlled clinical trial. In just two weeks with six treatments of Erchonia’s Verjú laser, patients experienced a significant improvement in the appearance of cellulite in their thighs, buttocks and lower abdomen when compared with those treated with the placebo laser. They also lost an average of 4.1 inches from their waists, hips and thighs.
Without incisions, pain or even heat, the green laser emulsifies adipose tissue beneath the skin to reduce the appearance of cellulite and contour the body. Patients can continue their daily routines immediately following treatment, and there is no downtime or pain whatsoever.
Charlie Shanks, vice president of Erchonia, says, “We are proud of the ‘firsts’ we’ve been able to accomplish with the launch of this laser. The Verjú is the first green laser to be cleared by the FDA and the first clinically-proven, noninvasive procedure to improve the appearance of cellulite. Verjú was able to deliver very impressive results in the clinical trial—all without any negative side effects of any kind.”
Dr. Mark S. Nestor, MD, PhD, comments, “I am very excited about the potential of low level laser technology, specifically this green wavelength, 532nm, for the reduction in appearance of cellulite. With this device, we have seen substantial benefit in overall fat reduction and improvement in ‘lumpiness’ which are the hallmarks of cellulite.”
The FDA has previously cleared Erchonia’s Zerona laser for the non-invasive circumference reduction of the arms and the waist, hips and thighs. Other Erchonia lasers are FDA-cleared for liposuction and breast augmentation assistance and the reduction of associated pain; for chronic neck and shoulder pain treatment; and for the treatment of acne. Erchonia has now been granted a total of (8) FDA 510k market clearances and are working on several others.
For more information, please visit http://www.erchonia.com.
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent level 1 clinical trials. Erchonia has garnered eight FDA 510 (k) market clearances and has several other products in research and development for new applications. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit http://www.erchonia.com.